Kamal Fariborz

Sociétés où Kamal Fariborz a négocié

• 4D Molecular Therapeutics, Inc.8 tx · $100K · Mar 10, 2025

Historique de performance de Kamal Fariborz

Historique insuffisant pour un historique de performance statistique (moins de 5 achats sur le marché).

Historique des transactions de Kamal Fariborz

Co-initiés de Kamal Fariborz

• BIOTECHNOLOGY VALUE FUND II LP4D Molecular Therapeutics, Inc.
• BIOTECHNOLOGY VALUE FUND L P4D Molecular Therapeutics, Inc.
• Biotechnology Value Trading Fund OS LP4D Molecular Therapeutics, Inc.
• Bizily Scott4D Molecular Therapeutics, Inc.
• Burkoth William T.4D Molecular Therapeutics, Inc.
• BVF GP HOLDINGS LLC4D Molecular Therapeutics, Inc.
• BVF I GP LLC4D Molecular Therapeutics, Inc.
• BVF II GP LLC4D Molecular Therapeutics, Inc.
• BVF INC/IL4D Molecular Therapeutics, Inc.
• BVF PARTNERS L P/IL4D Molecular Therapeutics, Inc.
• BVF Partners OS Ltd.4D Molecular Therapeutics, Inc.
• Chacko Jacob4D Molecular Therapeutics, Inc.
• FISHMAN ROBERT S4D Molecular Therapeutics, Inc.
• GRAY SUSANNAH4D Molecular Therapeutics, Inc.
• Gupta Ashoo4D Molecular Therapeutics, Inc.
• HALVORSEN OLE ANDREAS4D Molecular Therapeutics, Inc.
• Humer Kristian4D Molecular Therapeutics, Inc.
• Kasahara Noriyuki4D Molecular Therapeutics, Inc.
• Kim Robert Young4D Molecular Therapeutics, Inc.
• Kirn David4D Molecular Therapeutics, Inc.
• Kolchinsky Peter4D Molecular Therapeutics, Inc.
• LAMPERT MARK N4D Molecular Therapeutics, Inc.
• Mehra Uneek4D Molecular Therapeutics, Inc.
• Miller-Rich Nancy4D Molecular Therapeutics, Inc.
• MILLIGAN JOHN F4D Molecular Therapeutics, Inc.
• Moretti August J4D Molecular Therapeutics, Inc.
• Ott David C.4D Molecular Therapeutics, Inc.
• RA Capital Biotech Fund LP4D Molecular Therapeutics, Inc.
• RA CAPITAL MANAGEMENT, LLC4D Molecular Therapeutics, Inc.
• SBLENDORIO GLENN4D Molecular Therapeutics, Inc.
• SCHAFFER DAVID4D Molecular Therapeutics, Inc.
• Shabet Rose Sharon4D Molecular Therapeutics, Inc.
• Shah Rajeev M.4D Molecular Therapeutics, Inc.
• Simms Christopher Paul4D Molecular Therapeutics, Inc.